Updates in Treatment of Recurrent Clostridium difficile Infection
Abstract
Recurrent Clostridium difficile infection (CDI) is a perpetual problem that leads to increased economic burden, higher healthcare cost, and significant morbidity and mortality. Its treatment remains a challenge. While various treatment approaches have been attempted with different levels of success, robust data establishing the superiority of one approach over the others is lacking. In this article, we review the current evidence pertaining to conventional pharmacological treatment as well as fecal microbiota transplantation (FMT) as a novel, rapidly emerging treatment modality for recurrent CDI.
J Clin Med Res. 2019;11(7):465-471
doi: https://doi.org/10.14740/jocmr3854
J Clin Med Res. 2019;11(7):465-471
doi: https://doi.org/10.14740/jocmr3854
Keywords
Recurrent Clostridium difficile; Fecal microbiota transplantation; Tapering and pulsed vancomycin; Fidaxomicin